Jack, C. R. Jr et al. A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 87, 539–547 (2016).
Article CAS PubMed PubMed Central Google Scholar
Jack, C. R. Jr et al. NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 14, 535–562 (2018).
Article PubMed PubMed Central Google Scholar
Dubois, B. et al. Clinical diagnosis of Alzheimer’s disease: recommendations of the International Working Group. Lancet Neurol. 20, 484–496 (2021).
Article CAS PubMed PubMed Central Google Scholar
Brookmeyer, R. & Abdalla, N. Estimation of lifetime risks of Alzheimer’s disease dementia using biomarkers for preclinical disease. Alzheimers Dement. 14, 981–988 (2018).
Article PubMed PubMed Central Google Scholar
Dubois, B. et al. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer’s disease (INSIGHT-preAD): a longitudinal observational study. Lancet Neurol. 17, 335–346 (2018).
Article CAS PubMed Google Scholar
Donohue, M. C. et al. Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons. JAMA 317, 2305–2316 (2017).
Article CAS PubMed PubMed Central Google Scholar
Jack, C. R. Jr et al. Long-term associations between amyloid positron emission tomography, sex, apolipoprotein E and incident dementia and mortality among individuals without dementia: hazard ratios and absolute risk. Brain Commun. 4, fcac017 (2022).
Article PubMed PubMed Central Google Scholar
Nelson, P. T. et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J. Neuropathol. Exp. Neurol. 71, 362–381 (2012).
Ossenkoppele, R. et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease. Brain 139, 1551–1567 (2016).
Article PubMed PubMed Central Google Scholar
Ossenkoppele, R. et al. Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease. Neurology 92, e601–e612 (2019).
Article CAS PubMed PubMed Central Google Scholar
Jack, C. R. Jr et al. Associations of amyloid, tau, and neurodegeneration biomarker profiles with rates of memory decline among individuals without dementia. JAMA 321, 2316–2325 (2019).
Article CAS PubMed PubMed Central Google Scholar
Ossenkoppele, R., van der Kant, R. & Hansson, O. Tau biomarkers in Alzheimer’s disease: towards implementation in clinical practice and trials. Lancet Neurol. 21, 726–734 (2022).
Article CAS PubMed Google Scholar
Leuzy, A. et al. 2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework. Eur. J. Nucl. Med. Mol. Imaging 48, 2121–2139 (2021).
Article CAS PubMed PubMed Central Google Scholar
Fleisher, A. S. et al. Positron emission tomography imaging with [18F]flortaucipir and postmortem assessment of Alzheimer disease neuropathologic changes. JAMA Neurol. 77, 829–839 (2020).
Moloney, C. M., Lowe, V. J. & Murray, M. E. Visualization of neurofibrillary tangle maturity in Alzheimer’s disease: a clinicopathologic perspective for biomarker research. Alzheimers Dement. 17, 1554–1574 (2021).
Article CAS PubMed PubMed Central Google Scholar
Leuzy, A. et al. Diagnostic performance of RO948 F 18 tau positron emission tomography in the differentiation of Alzheimer disease from other neurodegenerative disorders. JAMA Neurol. 77, 955–965 (2020).
Ossenkoppele, R. et al. Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA 320, 1151–1162 (2018).
Article CAS PubMed PubMed Central Google Scholar
Young, C. B. et al. Divergent cortical tau positron emission tomography patterns among patients with preclinical Alzheimer disease. JAMA Neurol. 79, 592–603 (2022).
Johnson, K. A. et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann. Neurol. 79, 110–119 (2016).
Schöll, M. et al. PET imaging of tau deposition in the aging human brain. Neuron 89, 971–982 (2016).
Article PubMed PubMed Central Google Scholar
Gordon, B. A. et al. Tau PET in autosomal dominant Alzheimer’s disease: relationship with cognition, dementia and other biomarkers. Brain 142, 1063–1076 (2019).
Article PubMed PubMed Central Google Scholar
Pontecorvo, M. J. et al. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Brain 140, 748–763 (2017).
PubMed PubMed Central Google Scholar
Ossenkoppele, R. et al. Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer disease: a head-to-head comparison against amyloid positron emission tomography and magnetic resonance imaging. JAMA Neurol. 78, 961–971 (2021).
Article PubMed PubMed Central Google Scholar
Sperling, R. A. et al. The impact of amyloid-beta and tau on prospective cognitive decline in older individuals. Ann. Neurol. 85, 181–193 (2019).
CAS PubMed PubMed Central Google Scholar
Hanseeuw, B. J. et al. Association of amyloid and tau with cognition in preclinical Alzheimer disease: a longitudinal study. JAMA Neurol. 76, 915–924 (2019).
Article PubMed PubMed Central Google Scholar
Chen, S. D. et al. Staging tau pathology with tau PET in Alzheimer’s disease: a longitudinal study. Transl. Psychiatry 11, 483 (2021).
Article CAS PubMed PubMed Central Google Scholar
Bucci, M., Chiotis, K. & Nordberg, A. Alzheimer’s disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline. Mol. Psychiatry 26, 5888–5898 (2021).
Article CAS PubMed PubMed Central Google Scholar
Teng, E. et al. Baseline [18F]GTP1 tau PET imaging is associated with subsequent cognitive decline in Alzheimer’s disease. Alzheimers Res. Ther. 13, 196 (2021).
Article CAS PubMed PubMed Central Google Scholar
Biel, D. et al. Tau-PET and in vivo Braak-staging as prognostic markers of future cognitive decline in cognitively normal to demented individuals. Alzheimers Res. Ther. 13, 137 (2021).
Article CAS PubMed PubMed Central Google Scholar
Pontecorvo, M. J. et al. A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer’s disease dementia. Brain 142, 1723–1735 (2019).
Article PubMed PubMed Central Google Scholar
Cho, H. et al. Progressive tau accumulation in Alzheimer disease: 2-year follow-up study. J. Nucl. Med. 60, 1611–1621 (2019).
Article CAS PubMed PubMed Central Google Scholar
Strikwerda-Brown, C. et al. Association of elevated amyloid and tau positron emission tomography signal with near-term development of Alzheimer disease symptoms in older adults without cognitive impairment. JAMA Neurology 79, 975–985 (2022).
Wolters, E. E. et al. Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer’s disease in the context of a structured 5-phase biomarker development framework. Eur. J. Nucl. Med. Mol. Imaging 48, 2097–2109 (2021).
Article CAS PubMed PubMed Central Google Scholar
Papp, K. V., Rentz, D. M., Orlovsky, I., Sperling, R. A. & Mormino, E. C. Optimizing the preclinical Alzheimer’s cognitive composite with semantic processing: the PACC5. Alzheimers Dement. (N Y) 3, 668–677 (2017).
Pascoal, T. A. et al. 18F-MK-6240 PET for early and late detection of neurofibrillary tangles. Brain 143, 2818–2830 (2020).
Insel, P. S. et al. Determining clinically meaningful decline in preclinical Alzheimer disease. Neurology 93, e322–e333 (2019).
Article PubMed PubMed Central Google Scholar
Dumitrescu, L. et al. Genetic variants and functional pathways associated with resilience to Alzheimer’s disease. Brain 143, 2561–2575 (2020).
留言 (0)